The goal of the Lymphoma and Hodgkin Disease Program is to gain a better understanding of the biology underlying lymphoid neoplasms and to apply this knowledge to improve the diagnosis and treatment of these disorders. In working toward this goal, we have a broad research program with major themes of lymphoma pathogenesis, clinical pathological relationships, novel therapeutics and clinical trials. Our resources include a large clinical database of >10,000 lymphoma and 5,000 Hodgkin lymphoma over a follow-up period of 40 years and a tissue bank containing 5,500 fresh-frozen specimens. The 27 members within our program represent 11 departments within the School of Medicine and the School of Engineering. Investigators in the Lymphoma and Hodgkin Disease Program have 16 grants, including 1 P01;1 SCOR;1 P20;4 R01;1 T32;3 K and other peer-reviewed awards. The annual direct NCI support in 2008 totaled $3.5 million. Our program has emphasized translational research to the clinic in diagnostics and novel therapeutics and from the clinic to the laboratory in the correlation of studies on tissues matched with clinical events. During the past five years, over 300 publications have appeared in peer-reviewed journals. Laboratory-based projects are focused on the detection of signaling pathways in individual cells;lymphomagenesis, with attention to the MYC oncogene and the immune response to hepatitis C;development of novel diagnostics, including new gene discovery and new monoclonal antibodies directed against these genes;and model systems for a new method of therapeutic vaccination. Our clinical studies have a focus on immunotherapy and novel combined modality treatments and concepts from our group have moved into influential Phase III clinical trials in the Eastern Cooperative Oncology Group (ECOG).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications